BioArctic AB (publ) (BIOA-B) - Total Liabilities

Latest as of September 2025: Skr631.81 Million SEK ≈ $67.99 Million USD

Based on the latest financial reports, BioArctic AB (publ) (BIOA-B) has total liabilities worth Skr631.81 Million SEK (≈ $67.99 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore BIOA-B year-over-year net asset growth to track the company's year-over-year net asset growth rate.

BioArctic AB (publ) - Total Liabilities Trend (2015–2024)

This chart illustrates how BioArctic AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. See BioArctic AB (publ) free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.

BioArctic AB (publ) Competitors by Total Liabilities

The table below lists competitors of BioArctic AB (publ) ranked by their total liabilities.

Company Country Total Liabilities
Shanghai Tunnel Engineering Co Ltd
SHG:600820
China CN¥137.99 Billion
Zhejiang Orient Holdings Co Ltd
SHG:600120
China CN¥44.10 Billion
Comet Holding AG
SW:COTN
Switzerland CHF199.23 Million
Peabody Energy Corp
NYSE:BTU
USA $2.17 Billion
Shanghai Jin Jiang International Hotels Development Co Ltd A
SHG:600754
China CN¥30.00 Billion
Klaviyo, Inc.
NYSE:KVYO
USA $384.04 Million
NIB Holdings Ltd
AU:NHF
Australia AU$992.90 Million
McGrath RentCorp
NASDAQ:MGRC
USA $1.12 Billion

Liability Composition Analysis (2015–2024)

This chart breaks down BioArctic AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see BioArctic AB (publ) stock valuation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 4.18 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio 1.84 Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.32 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.24 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how BioArctic AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for BioArctic AB (publ) (2015–2024)

The table below shows the annual total liabilities of BioArctic AB (publ) from 2015 to 2024.

Year Total Liabilities Change
2024-12-31 Skr216.74 Million
≈ $23.32 Million
+55.37%
2023-12-31 Skr139.50 Million
≈ $15.01 Million
+93.58%
2022-12-31 Skr72.06 Million
≈ $7.76 Million
-33.92%
2021-12-31 Skr109.05 Million
≈ $11.74 Million
-23.75%
2020-12-31 Skr143.01 Million
≈ $15.39 Million
-31.52%
2019-12-31 Skr208.84 Million
≈ $22.47 Million
-44.36%
2018-12-31 Skr375.31 Million
≈ $40.39 Million
-25.59%
2017-12-31 Skr504.35 Million
≈ $54.28 Million
-22.07%
2016-12-31 Skr647.22 Million
≈ $69.65 Million
+2735.43%
2015-12-31 Skr22.83 Million
≈ $2.46 Million
--

About BioArctic AB (publ)

ST:BIOA-B Sweden Biotechnology
Market Cap
$2.60 Billion
Skr24.13 Billion SEK
Market Cap Rank
#5274 Global
#73 in Sweden
Share Price
Skr325.00
Change (1 day)
+0.62%
52-Week Range
Skr214.80 - Skr364.40
All Time High
Skr377.80
About

BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and other CNS diseases. In addition, … Read more